Purchase this article with an account.
Patricia Udaondo, SALVADOR GARCIA-DELPECH, DAVID SALOM, Ana Hervas-Ontiveros, Ricardo Diaz-Cespedes; AFLIBERCEPT IN TREATMENT-NAÏVE PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: PROSPECTIVE PILOT STUDY. Invest. Ophthalmol. Vis. Sci. 2016;57(12):542.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting
Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), three loading doses of 2 mg (0.05 mL) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months.
At 3 and 13 months, the mean best-corrected visual acuity (BCVA) improved significantly as compared with baseline (logMAR 0.53 ± 0.30 and 0.55 ± 0.32 vs. 0.30 ± 0.24, respectively, P < 0.001). At 3 and 13 months, 46.8% of patients (n = 15) gained ≥ 15 EDTRS letters. The mean decrease in central macular thickness was also significant at 3 months (252 ± 35 µm) and at 13 months (249 ± 38 µm) as compared with pre-treatment values (383 ± 76 µm) (P < 0.01). Also, 50% resolution of pigment epithelial detachment (PED) was observed in 8 of 9 eyes (88.9%) with PDE at baseline. Intravitreal injections were well tolerated and no adverse events were recorded.
Aflibercept was effective and safe for treating nvAMD in naïve patients in routine daily practice.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only